A cell transmembrane peptide chimeric M(27-39)-HTPP targeted therapy for hepatocellular carcinoma

Area of Science:

• Oncology
• Peptide Therapeutics
• Biotechnology

Background:

• Hepatocellular carcinoma (HCC) is a major global health concern with increasing incidence and mortality.
• Current HCC treatment strategies face challenges in tumor targeting, penetration, and inhibiting cancer cell proliferation, migration, and invasion.

Purpose of the Study:

• To develop and evaluate a novel peptide conjugate, M(27-39)-HTPP, for targeted HCC therapy.
• To assess the efficacy of M(27-39)-HTPP in inhibiting HCC progression and inducing apoptosis.
• To determine the biosecurity of M(27-39)-HTPP at therapeutic doses.

Main Methods:

• Synthesis of M(27-39)-HTPP by conjugating the M27-39 peptide with the HTPP liver-targeting peptide.
• In vitro and in vivo evaluation of M(27-39)-HTPP's tumor targeting and penetration capabilities.
• Assessment of M(27-39)-HTPP's effects on HCC cell proliferation, migration, invasion, and apoptosis.
• Biosecurity evaluation of M(27-39)-HTPP in therapeutic settings.

Main Results:

• M(27-39)-HTPP demonstrated significant tumor targeting and penetration abilities in HCC models.
• The peptide conjugate effectively inhibited HCC cell proliferation, migration, and invasion.
• M(27-39)-HTPP successfully induced apoptosis in HCC cells.
• The therapeutic peptide exhibited good biosecurity at effective doses.

Conclusions:

• M(27-39)-HTPP is a promising novel therapeutic peptide for hepatocellular carcinoma.
• The conjugate offers a safe and efficient approach for targeting and treating HCC.
• Further development of M(27-39)-HTPP could lead to improved clinical outcomes for HCC patients.